Galrinho Ruxandra Dragoi, Manole Catalin Gabriel, Vinereanu Dragos
"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania ; University and Emergency Hospital, Bucharest, Romania ; "Victor Babes" National Institute of Research Development in the Pathology Domain and Biomedical Sciences, Bucharest, Romania.
"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania ; "Victor Babes" National Institute of Research Development in the Pathology Domain and Biomedical Sciences, Bucharest, Romania.
Maedica (Bucur). 2016 Dec;11(4):325-329.
Cardiovascular diseases, particularly myocardial infarction, remain the leading cause of morbidity and mortality worldwide, even though pharmacological and interventional therapies improved significantly in the last years. Moreover, despite encouraging results of cell - based therapies in experimental myocardial infarction models, clinical trials showed inconsistent and modest efficiency. Therefore the next step should be the revealing of a new cell type, capable of regenerating the damaged myocardium. Telocytes (TCs), a relatively new type of interstitial cells, were described few years ago and are credited with important roles in regenerative therapies. In this paper we review their most important characteristics and functions, showing the evidences of their potential role in cardiac repair and regeneration. Our research leads to the conclusion that TCs might be a novel target for therapeutic strategies in myocardial infarction.
心血管疾病,尤其是心肌梗死,仍然是全球发病和死亡的主要原因,尽管在过去几年里药物和介入治疗有了显著改善。此外,尽管基于细胞的疗法在实验性心肌梗死模型中取得了令人鼓舞的结果,但临床试验显示其疗效并不一致且效果有限。因此,下一步应该是发现一种能够使受损心肌再生的新型细胞类型。端细胞(TCs)是一种相对新型的间质细胞,几年前被描述出来,并被认为在再生治疗中发挥重要作用。在本文中,我们综述了它们最重要的特征和功能,展示了它们在心脏修复和再生中潜在作用的证据。我们的研究得出结论,端细胞可能是心肌梗死治疗策略的一个新靶点。